Search

Displaying results 4291 - 4300 of 10000 in total
  1. Drug

    Neisseria meningitidis group y capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10800
    ApprovedInvestigational

    grown in another culture. … Neisseria meningitidis group y capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria

  2. Drug

    Mitumomab

    go.drugbank.com/drugs/DB06462
    Experimental

    Mitumomab, an anti-BEC-2 monoclonal antibody derived from mice, was previously studied to treat small cell lung carcinoma in combination with BCG vaccination.

  3. Drug

    Epicriptine

    go.drugbank.com/drugs/DB11275
    Approved

    Epicriptine differs from the alpha form on the position of one methyl group.[T195] To know more about the mixture please visit [DB01049]

  4. Drug

    Bevantolol

    go.drugbank.com/drugs/DB01295
    Investigational

    Mechanism of Action Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors.

  5. Drug

    DNB-001

    go.drugbank.com/drugs/DB05757
    Investigational

    In preclinical animal models, DNB-001 has demonstrated potent IOP- lowering effects as well as neuroprotective effects on the optic nerve. … DNB-001 is a first-in-class oral therapy with dual mechanism of action, which is initially being developed for the treatment of glaucoma.

  6. Drug

    Danvatirsen

    go.drugbank.com/drugs/DB14825
    Investigational

    Danvatirsen is under investigation in clinical trial NCT03334617 (Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.).

  7. Drug

    C31G

    go.drugbank.com/drugs/DB05398
    Investigational

    is a potent broad spectrum antimicrobial agent, effective against gram positive and gram negative bacteria, yeast and fungi.C31G, vaginal gel is developed by Biosyn Inc. and has commenced enrollment in

  8. Drug

    Dehydrocholic acid

    go.drugbank.com/drugs/DB11622
    Approved

    The use of dehydrocholic acid in over-the-counter products has been discontinued by Health Canada.

  9. Drug

    Rintodestrant

    go.drugbank.com/drugs/DB21472
    Investigational

    Rintodestrant is under investigation in clinical trial NCT03455270 (G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer).

  10. Drug

    Nomifensine

    go.drugbank.com/drugs/DB04821
    ApprovedWithdrawn

    The approved application holder removed Merital capsules from the market on January 23, 1986. … Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia.